154 related articles for article (PubMed ID: 38730705)
1. Antiretroviral Drug Repositioning for Glioblastoma.
Rivas SR; Mendez Valdez MJ; Chandar JS; Desgraves JF; Lu VM; Ampie L; Singh EB; Seetharam D; Ramsoomair CK; Hudson A; Ingle SM; Govindarajan V; Doucet-O'Hare TT; DeMarino C; Heiss JD; Nath A; Shah AH
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730705
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Properties of the Antipsychotic Drug Chlorpromazine and Its Synergism With Temozolomide in Restraining Human Glioblastoma Proliferation
Matteoni S; Matarrese P; Ascione B; Buccarelli M; Ricci-Vitiani L; Pallini R; Villani V; Pace A; Paggi MG; Abbruzzese C
Front Oncol; 2021; 11():635472. PubMed ID: 33718225
[TBL] [Abstract][Full Text] [Related]
3. A multiparametric pharmacogenomic strategy for drug repositioning predicts therapeutic efficacy for glioblastoma cell lines.
Shah AH; Suter R; Gudoor P; Doucet-O'Hare TT; Stathias V; Cajigas I; de la Fuente M; Govindarajan V; Morell AA; Eichberg DG; Luther E; Lu VM; Heiss J; Komotar RJ; Ivan ME; Schurer S; Gilbert MR; Ayad NG
Neurooncol Adv; 2022; 4(1):vdab192. PubMed ID: 35118385
[TBL] [Abstract][Full Text] [Related]
4. Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma.
Yadav A; Alnakhli A; Vemana HP; Bhutkar S; Muth A; Dukhande VV
Pharm Res; 2022 Nov; 39(11):2871-2883. PubMed ID: 36195821
[TBL] [Abstract][Full Text] [Related]
5. Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery-A Comprehensive Review of the Literature.
Alomari S; Zhang I; Hernandez A; Kraft CY; Raj D; Kedda J; Tyler B
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944514
[TBL] [Abstract][Full Text] [Related]
6. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential
Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112
[TBL] [Abstract][Full Text] [Related]
7. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT
J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
[TBL] [Abstract][Full Text] [Related]
9. Integrative rare disease biomedical profile based network supporting drug repurposing or repositioning, a case study of glioblastoma.
McGowan E; Sanjak J; Mathé EA; Zhu Q
Orphanet J Rare Dis; 2023 Sep; 18(1):301. PubMed ID: 37749605
[TBL] [Abstract][Full Text] [Related]
10. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
[No Abstract] [Full Text] [Related]
11. An Alternative Pipeline for Glioblastoma Therapeutics: A Systematic Review of Drug Repurposing in Glioblastoma.
Lyne SB; Yamini B
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33919596
[TBL] [Abstract][Full Text] [Related]
12. A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells.
Dogra N; Singh P; Kumar A
Mol Neurobiol; 2024 Apr; ():. PubMed ID: 38619743
[TBL] [Abstract][Full Text] [Related]
13. Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
Teng J; Hejazi S; Hiddingh L; Carvalho L; de Gooijer MC; Wakimoto H; Barazas M; Tannous M; Chi AS; Noske DP; Wesseling P; Wurdinger T; Batchelor TT; Tannous BA
Neuro Oncol; 2018 Apr; 20(5):642-654. PubMed ID: 29099956
[TBL] [Abstract][Full Text] [Related]
14. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
[TBL] [Abstract][Full Text] [Related]
15. Differential gene expression-based connectivity mapping identified novel drug candidate and improved Temozolomide efficacy for Glioblastoma.
Vengoji R; Atri P; Macha MA; Seshacharyulu P; Perumal N; Mallya K; Liu Y; Smith LM; Rachagani S; Mahapatra S; Ponnusamy MP; Jain M; Batra SK; Shonka N
J Exp Clin Cancer Res; 2021 Oct; 40(1):335. PubMed ID: 34696786
[TBL] [Abstract][Full Text] [Related]
16. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia drives shared and distinct transcriptomic changes in two invasive glioma stem cell lines.
Marallano VJ; Ughetta ME; Tejero R; Nanda S; Ramalingam R; Stalbow L; Sattiraju A; Huang Y; Ramakrishnan A; Shen L; Wojcinski A; Kesari S; Zou H; Tsankov AM; Friedel RH
Sci Rep; 2024 Mar; 14(1):7246. PubMed ID: 38538643
[TBL] [Abstract][Full Text] [Related]
18. Biological basis and clinical study of glycogen synthase kinase- 3β-targeted therapy by drug repositioning for glioblastoma.
Furuta T; Sabit H; Dong Y; Miyashita K; Kinoshita M; Uchiyama N; Hayashi Y; Hayashi Y; Minamoto T; Nakada M
Oncotarget; 2017 Apr; 8(14):22811-22824. PubMed ID: 28423558
[TBL] [Abstract][Full Text] [Related]
19. Different states of stemness of glioblastoma stem cells sustain glioblastoma subtypes indicating novel clinical biomarkers and high-efficacy customized therapies.
Visioli A; Trivieri N; Mencarelli G; Giani F; Copetti M; Palumbo O; Pracella R; Cariglia MG; Barile C; Mischitelli L; Soriano AA; Palumbo P; Legnani F; DiMeco F; Gorgoglione L; Pesole G; Vescovi AL; Binda E
J Exp Clin Cancer Res; 2023 Sep; 42(1):244. PubMed ID: 37735434
[TBL] [Abstract][Full Text] [Related]
20. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
